Ensuring Patient Access and Open Strategic Autonomy in Europe: PPTA’s Recommendations for the Critical Medicines Act

Plasma Protein Therapeutics Association (PPTA) calls on policymakers to ensure that the Critical Medicines Act includes tailored provisions that address the unique characteristics of plasma-derived medicinal products (PDMPs).